Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy
JAMA Neurol 81:83-84, Hua,L.,et al, 2024
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
A 56-year-old Man with Cognitive Impairment and Difficulty Tying his Necktie
Neurol 85:e116-e122, Baker, J.M.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
A Meta-Regression of the Long-Term Effects of Deep Brain Stimulation on Balance and Gait in PD
Neurol 75:1292-1299, St. George,R.J.,et al, 2010
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
Vascular Parkinsonism and Dementia in a CADASIL Case with Intact Nigrostriatal Dopaminergic System
Akt Neurol 33: Suppl, Wegner,F.,et al, 2006
The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005
Awakenings From Persistent Vegetative State: Report of Three Cases With Parkinsonism and Brain Stem Lesions on MRI
JNNP 74:1571-1573, Matsuda,W.,et al, 2003
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Long-Term Follow-Up of Levodopa Responsiveness in Generalized Dystonia
Arch Neurol 55:1320-1323, Dewey,R.B.,et al, 1998
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Levodopa-Nonresponsive Lewy Body Parkinsonism:Clinicopathologic Study of Two Cases
Neurol 42:1323-1327, Mark,M.H.,et al, 1992
Dopa-Responsive Dystonia:Long-Term Treatment Response and Prognosis
Neurol 41:174-181, Nygaard,T.G.,et al, 1991
Young-Onset Parkinson's Disease:A Clinical Review
Neurol 41:168-173, Golbe,L.I., 1991
Mortality Associated with Early and Late Levodopa Therapy Initiation in Parkinson's Disease
Neurol 40:265-269, Scigliano,G.,et al, 1990
Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975